Skip Navigation

Corrigendum for Redfern et al., Cardiovasc Res 58 (1) 32-45.
Cardiovascular Research 2004 63(1):186-187; doi:10.1016/j.cardiores.2004.04.016
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Redfern, W.S
Right arrow Articles by Hammond, T.G
Right arrow Search for Related Content
PubMed
Right arrow Articles by Redfern, W.S
Right arrow Articles by Hammond, T.G
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

Corrigendum to "Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development" [Cardiovasc. Res. 58 (2003) 32–45]

W.S Redferna, L Carlssonb, A.S Davisc, W.G Lynchd, I MacKenziee, S Palethorpea, P.K.S Sieglf, I Stranga, A.T Sullivang, R Wallish, A.J Cammi and T.G Hammond*,a

aSafety Assessment UK, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire SK10 4TG, UK
bCardiovascular Pharmacology, AstraZeneca R&D Mölndal, 431 83 Mölndal, Sweden
cAnimal Welfare Group, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire SK10 4TG, UK
dDrug Safety, AstraZeneca R&D Charnwood, Loughborough, Leicestershire LE11 5RH, UK
eCovance Laboratories Limited, Otley Road, Harrogate, North Yorks HG3 1PY, UK
fMerck Research Laboratories, P.O. Box 4, West Point, PA 19486-00047, USA
gGlaxoSmithKline Safety Assessment, The Frythe, Welwyn, Herts, AL6 9AR, UK
hPfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
iDepartment of Cardiological Sciences, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK

*Corresponding author. Tel.: +44-1625 514810; fax: +44-1625513779. Email address: tim.hammond@astrazeneca.com

The first 10% of the full text of this article appears below.

The following minor errors and potential ambiguities have been brought to our attention since publication of the article. None of these affect the interpretation of the data or overall conclusions.

1. The reference [36] cited for the single report of torsade de pointes with fluoxetine (p. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?